60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
60 Degrees Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -729.9%. For fiscal 2025 it was -732.5%, against -1308.0% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -732.5% | +575.5 |
| FY2024 | Dec 31, 2024 | -1308.0% | +177.0 |
| FY2023 | Dec 31, 2023 | -1485.1% | +1284.4 |
| FY2022 | Dec 31, 2022 | -2769.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1089.2% | +628.5 |
| Q1 FY2026 | Mar 31, 2026 | -1288.9% | −141.5 |
| Q4 FY2025 | Dec 31, 2025 | -474.2% | +372.2 |
| Q3 FY2025 | Sep 30, 2025 | -529.3% | +1067.1 |
| Q2 FY2025 | Jun 30, 2025 | -1717.7% | +1621.2 |
| Q1 FY2025 | Mar 31, 2025 | -1147.4% | −1554.7 |
| Q4 FY2024 | Dec 31, 2024 | -846.3% | +754.8 |
| Q3 FY2024 | Sep 30, 2024 | -1596.4% | −9768.6 |
| Q2 FY2024 | Jun 30, 2024 | -3339.0% | +2265.7 |
| Q1 FY2024 | Mar 31, 2024 | 407.4% | +15548.6 |
| Q4 FY2023 | Dec 31, 2023 | -1601.1% | −740.4 |
| Q3 FY2023 | Sep 30, 2023 | 8172.2% | +12924.8 |
| Q2 FY2023 | Jun 30, 2023 | -5604.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -15141.3% | – |
| Q3 FY2022 | Sep 30, 2022 | -860.7% | – |
| Q2 FY2022 | Jun 30, 2022 | -4752.6% | – |